Mineralys Therapeutics Inc（MLYS）の株式分析MLYSMineralys Therapeutics Inc

Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Mineralys Therapeutics Inc (MLYS) is not a strong buy due to its recent performance and financial metrics. The stock is trading at $25.60, down 28.31% year-to-date, indicating significant volatility. The RSI is at 40.695, suggesting it is nearing oversold territory, but still not a clear buy signal. Additionally, the company reported a substantial loss of $241 million in Q2 2026, which raises concerns about its profitability and future cash flow. The main risk is the negative earnings per share (EPS) of -2.85, reflecting ongoing financial struggles despite a positive analyst outlook.